Circulating biomarkers of collagen metabolism in arterial hypertension: Relevance of target organ damage

Journal of Hypertension

Volumn 31, Issue 8, 2013, Pages 1611-1617

  Morillas, Pedro ^a   Quiles, Juan ^a   De Andrade, Helder ^a   Castillo, Jesus ^a   Tarazón, Estefanía ^b   Roselló, Esther ^b   Portolés, Manuel ^b   Rivera, Miguel ^b   Bertomeu Martínez, Vicente ^a  

^a HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

arterial remodeling; blood pressure; collagen; matrix metalloproteinases; target organ damage

Indexed keywords

ANTIHYPERTENSIVE AGENT; COLLAGEN; COLLAGEN TYPE 1; INTERSTITIAL COLLAGENASE; PLASMA PROCOLLAGEN TYPE 1; PROCOLLAGEN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

ADULT; AGE; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD VESSEL; BLOOD VESSEL INJURY; COLLAGEN METABOLISM; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; ESSENTIAL HYPERTENSION; FEMALE; HEART INJURY; HUMAN; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; PERIMETER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING;

EID: 84880572886     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283614c1c     Document Type: Article

References (26)

1. Fontana V, Silva P, Gerlach R, Tanus-Santos JE. Circulating matrix metalloproteinases and their inhibitors in hypertension. Clin Chim Acta 2012; 413:656-662.
2. Liu P, Sun M, Sader S. Matrix metalloproteinases in cardiovascular disease. Can J Cardiol 2006; 22:25B-30B.
3. Castro M, Tanus-Santos JE, Gerlach R. Matrix metalloproteinases: targets for doxycycline to prevent the vascular alterations of hypertension. Pharmacol Res 2011; 64:567-572.
4. Marchesi C, Dentali F, Nicolini E, Maresca AM, Tayebjee MH, Franz M, et al. Plasma levels of matrix metalloproteinases and their inhibitors in hypertension: a systematic review and meta-analysis. J Hypertens 2012; 30:3-16.
5. Hansson J, Lind L, Hulthe J, SundstromJ. Relations of serum MMP-9 and TIMP-1 levels to left ventricular measures and cardiovascular risk factors: a population-based study. Eur J Cardiovasc Prev Rehabil 2009; 16:297-303.
6. Zile MR, Desantis SM, Baicu CF, Stroud RE, Thompson SB, McClure CD, et al. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail 2011; 4:246-256 /
7. Tendera M, Aboyans V, Bartelink ML, Baumgartner I, Clement D, Collet JP, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27:2121-2158.
8. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's guidelines and standard committee and the camber quantification writing group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440-1463.
9. Beaumont J, Gonzalez A, Lopez B, Ravassa S, Diez J. Contribution of circulating biomarkers to unravel the role of extracellular matrix in hypertensive cardiac remodeling. J Hypertens 2012; 30: 34-37.
10. Querejeta R, Lopez B, Gonzalez A, Sanchez E, Larman M, Martinez Ubago JL, et al. Increased collagen type I synthesis in patient with heart failure of hypertensive origin. Relation to myocardial fibrosis. Circulation 2004; 110:1263-1268.
11. Lopez B, Gonzalez A, Querejeta R, Diez J. The use of collagen-derived serum peptides for the clinical assessment of hypertensive heart disease. J Hypertens 2005; 23:1445-1451.
12. Martos R, Baugh J, Ledwige M, O' Loughlin C, Conlon C, Patle A, et al. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 2007; 115:888-895.
13. Muller-Brunotte R, Kahan T, Lopez B, Edner M, Gonzalez A, Diez J, et al. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). J Hypertens 2007; 25:1958-1966.
14. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69:562-573.
15. Castro MM, Rizzi E, Figueiredo-Lopes L, Fernandes K, Bendhack LM, Pitol DL, et al. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 2008; 198:320-331.
16. Lopez D, Gonzalez A, Diez J. Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation 2010; 121:1645-1654.
17. 2+; channel antagonists on plasma concentrations of matrix metalloproteinase-2 and -9 in essential hypertension. Am J Hypertens 2004; 17:273-276.
18. Ergul A, Portik-Dobos V, Hutchinson J, Franco J, Anstadt MP. Downregulation of vascular matrix metalloproteinase inducer and activator proteins in hypertensive patients. Am J Hypertens 2004; 17:775-782.
19. Laviades C, Varo N, Fernandez J, Mayor G, Gil MJ, Monreal I, Diez J. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998; 98:535-540.
20. Tayebjee MH, Nadar S, Blann AD, Gareth Beevers D, MacFadyen RJ, Lip GY. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment. Am J Hypertens 2004; 17:764-769.
21. Derosa G, D'Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, et al. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase- 1 in patients with hypertension. Endothelium 2006; 13:227-231.
22. Friese RS, Rao F, Khandrika S, Thomas B, Ziegler MG, Schmid- Schonbein GW, et al. Matrix metalloproteinases: discrete elevations in essential hypertension and hypertensive end-stage renal disease. Clin Exp Hypertens 2009; 31:521-533.
23. Lindsay MM, Maxwell P, Dunn FG. TIMP-1: a marker of left ventricular diastolic dysfunction and fibrosis in hypertension. Hypertension 2002; 40:136-141.
24. Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006; 113:2089-2096.
25. Gonzalez A, Lopez B, Querejeta R, Zubillaga E, Echeverria T, Diez J. Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction. Hypertension 2010; 55:1418-1424.
26. Li-Saw-Hee F, Edmunds E, Blann A, Beevers D, Lip G. Matrix metalloproteinase- 9 and tissue inhibitor of metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and antihypertensive therapy. Int J Cardiol 2000; 75:43-47.